Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Key facts

Sponsor

University College, London

Intervention

Ganfeborole(drug)

Enrollment

2500 target

Eligibility

18 years · All sexes

Timeline

2024 – 2027

Study locations (11)

• PMSI Institute of Pneumology "Chiril Draganiuc", Chisinau, Moldova
• TASK Brooklyn, Cape Town, South Africa
• University of Cape Town Lung Institute, Cape Town, South Africa
• TASK Eden, George, South Africa
• NIMR Mbeya, Mbeya, Tanzania
• Kibong'oto Infectious Diseases Hospital, Moshi, Tanzania
• NIMR Mwanza, Mwanza, Tanzania
• Joint Clinical Research Centre, Kampala, Uganda
• Makerere University Lung Institute, Kampala, Uganda
• National Lung Hospital, Hanoi, Vietnam
• Pnth/Oucru, Ho Chi Minh City, Vietnam

Collaborators

Radboud University Medical Center · London School of Hygiene and Tropical Medicine · University of Oxford · Research Center Borstel · Lygature · TASK Applied Science · Vita-Salute San Raffaele University · Helmholtz Zentrum Munchen · KNCV Tuberculosis Foundation · Critical Path Institute · European Lung Foundation · Instituto de Saude Publica da Universidade do Porto · University of Liverpool · Institut de Recherche pour le Developpement · University of Hamburg-Eppendorf · University of California, San Francisco · TB Alliance · Find · University of Milano · University of St Andrews · Uppsala University · European Respiratory Society · Tuberculosis Network European Trialsgroup · Janssen, LP · Otsuka Pharmaceutical Development & Commercialization, Inc. · German Center for Infection Research · LMU University Hospital Munich · University of Cambridge · GlaxoSmithKline

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07484490
  Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis
  Riphah International University
• RECRUITINGPHASE3NCT07209761
  A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
  Otsuka Pharmaceutical Development & Commercialization, Inc.
• RECRUITINGPHASE2NCT07170800
  A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
  WestVac Biopharma Co., Ltd.
• RECRUITINGPHASE2NCT06192160
  Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGPHASE2NCT06748937
  A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
  TASK Applied Science
• ACTIVE NOT RECRUITINGNANCT07186478
  I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis
  Hasanuddin University
• ACTIVE NOT RECRUITINGPHASE3NCT06649721
  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
  Huashan Hospital
• RECRUITINGPHASE4NCT06476210
  The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)
  Beijing Chest Hospital

See all trials for Primary pulmonary tuberculosis →